Commercializes prescription topical medicines for skin conditions, including ZELSUVMI for molluscum contagiosum, XEPI for impetigo and XEGLYZE for head lice; sells ZELSUVMI to pharmaceutical wholesalers.
10-K for FY2025, filed Mar 19, 2026Pelthos Therapeutics Inc. (the “Company”) is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious…View ↗
ZELSUVMI (berdazimer) topical gel, 10.3% is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum…View ↗
XEPI is a novel FDA-approved non-fluorinated quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus…View ↗
In December 2025, the Company acquired XEGLYZE (abametapir) for the topical treatment of head lice. XEGLYZE is a pediculicide indicated for…View ↗
The Company primarily sells its ZELSUVMI product to national and regional wholesaler channels. Our wholesalers purchase products from us…View ↗
Wholesalers pay for ZELSUVMI when it is delivered. The out-license brings revenue at license delivery and as related development work progresses.
10-K for FY2025, filed Mar 19, 2026The Company currently sells ZELSUVMI to national and regional wholesalers in the United States. Revenue from product sales is recognized…View ↗
The Company concluded that Sato is a customer with respect to all promises in the Amended Sato Agreement, and as such, revenue is…View ↗
A portion of transaction price allocated to license performance obligation was recognized in revenues on the date of license delivery. For…View ↗
$16.8M
10-K for FY2025, filed Mar 19, 2026
$16.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product revenues
Sold outright
10-K for FY2025, filed Mar 19, 2026 |
96% |
Net product revenues, FY2025
$16.2M Sources
|
Sold outright |
|
License and collaboration revenues
Licensed
|
3.5% |
License and collaboration revenues, FY2025
$589K Sources
|
Licensed |
Pelthos sells ZELSUVMI to national and regional wholesalers, which supply retail drugstore chains, independent pharmacies and mail-order pharmacies.
10-K for FY2025, filed Mar 19, 2026
Financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash, cash equivalents…View ↗
No. It lost $43.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$7.9MView ↗
8-K, filed Oct 30, 2026
On October 30, 2026, Pelthos Therapeutics Inc., a Nevada corporation (“Pelthos” or “Public Company”), Credit Card Merger Sub, Inc., a…View ↗
8-K, filed Aug 13, 2026
On August 12, 2026, the audit committee of our board of directors (the “Audit Committee”), in consultation with management, concluded that…View ↗
8-K, filed May 21, 2026
On May 16, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Pelthos Therapeutics Inc. (the…View ↗
Loading...